A major new study reveals that some people's brains can resist dementia even when they have significant Alzheimer's pathology, and the key may lie in how immune cells respond to disease. Researchers from VIB, KU Leuven, and other institutions examined brain tissue from older adults with and without cognitive decline, including cognitively healthy centenarians, and identified distinct immune cell patterns that either protect against or accelerate dementia.

Why Do Some People Stay Sharp Despite Brain Damage?

For decades, scientists assumed that the buildup of amyloid-beta plaques and tau tangles in the brain directly caused dementia. But this assumption doesn't match reality. Many people accumulate substantial amounts of these toxic proteins yet remain cognitively healthy, while others with similar pathology develop severe memory loss and confusion. This puzzle has driven researchers to look beyond the plaques themselves and examine how brain cells respond to them.

The new research, published in Nature Medicine, focused on microglia, which are the brain's resident immune cells. These cells normally help monitor and protect the brain, but their behavior changes dramatically as Alzheimer's advances. By comparing brain tissue from people with dementia, people without dementia, and cognitively healthy centenarians, researchers identified different microglial responses associated with protection from the disease's effects.

"Understanding better how the brain resists the disease will provide new avenues towards therapies to prevent neurodegeneration and dementia," explained Mark Fiers, co-senior author of the study at VIB-KU Leuven.

Mark Fiers, Co-Senior Author, VIB-KU Leuven

What Is the Critical Turning Point in Alzheimer's?

Using advanced cell-level analysis techniques, the research team identified six distinct tissue domains representing different stages of Alzheimer's progression. One especially important transition separated regions dominated by amyloid-beta plaques from those associated with tau pathology and neurodegeneration. This shift was accompanied by a major change in how microglia behaved.

During the earlier stages of disease, microglia entered an inflammatory state linked to amyloid plaques. At a later stage, they shifted into a different immune state called antigen-presenting, which appeared at the same time as tau pathology and brain cell damage. This transition may mark a biological turning point that determines whether Alzheimer's pathology continues toward dementia.

How Do Different People Achieve Resilience?

The study revealed that resilience doesn't look the same in everyone. The researchers identified two distinct biological pathways that protect against dementia:

• The Octogenarian Path: Older adults who had developed amyloid plaques but remained free of dementia showed the early microglial response to amyloid. However, their microglia did not transition into the later immune state associated with disease progression, essentially stopping the cascade before it caused damage.
• The Centenarian Path: People over 100 years old activated the later microglial program, but this response occurred largely without being tied to tau accumulation. In other words, a cellular state that was associated with neurodegeneration in some people appeared to be separated from damaging effects in others.
• The Flexibility Factor: These findings suggest that resilience is not simply a matter of avoiding Alzheimer's pathology. It may also depend on how the brain controls, redirects, or adapts its response to that pathology, offering multiple routes to protection.

This discovery challenges the idea that there is only one way to resist dementia. Instead, it suggests that the brain can achieve cognitive resilience through different biological mechanisms.

What Could This Mean for Future Alzheimer's Treatments?

The results could support the development of more precise Alzheimer's therapies. Instead of focusing only on removing amyloid plaques, future treatments might aim to preserve beneficial early microglial activity or influence the transition between different microglial states. Molecules involved in these shifts could become valuable therapeutic targets.

Timing may also be critical. Treatments could be most effective before the brain reaches the point where inflammatory activity becomes connected to tau pathology, neurodegeneration, and cognitive decline. This suggests that early intervention, before symptoms appear, might be more effective than waiting until dementia develops.

"These findings open new opportunities to target microglial states, especially pathways such as TREM2, and extend resilience rather than simply focusing on plaque removal," noted Niels Plath, Chief Scientific Officer of Muna Therapeutics.

Niels Plath, Chief Scientific Officer, Muna Therapeutics

How Should This Research Change Our Approach to Dementia?

The broader context of neurodegenerative disease research is shifting away from the idea that diseases like Alzheimer's are purely defined by single proteins or pathologies. Recent evidence shows that mixed pathologies are the rule, not the exception. For example, 50 to 80 percent of individuals with dementia with Lewy bodies have both alpha-synuclein and amyloid-beta oligomers, and Alzheimer's and Parkinson's pathologies often overlap.

This means that future treatments may need to target multiple pathogenic proteins while simultaneously addressing shared inflammatory pathways. The immune response, particularly the behavior of microglia, appears to be a critical shared mechanism across different types of neurodegeneration.

The new findings also highlight the importance of biomarker-driven approaches to diagnosis and treatment. Blood-based assays can now measure markers of amyloid-beta, tau, and neuroinflammatory activity at earlier stages, potentially decades before symptoms appear. This offers an opportunity for early detection and intervention before irreversible neuronal damage occurs.

For people concerned about their cognitive health, this research underscores that having Alzheimer's pathology in the brain does not automatically mean dementia will develop. The brain has multiple ways to protect itself, and understanding these protective mechanisms could lead to treatments that extend cognitive resilience and prevent or delay the onset of dementia symptoms.